Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FNCHNASDAQ:GALTNASDAQ:IMUXNASDAQ:IZTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$13.75+6.8%$13.11$1.10▼$15.85$22.08M1.252,186 shs402 shsGALTGalectin Therapeutics$1.37+2.2%$1.33$0.73▼$3.17$86.71M0.54320,613 shs187,662 shsIMUXImmunic$0.80-4.6%$0.95$0.56▼$2.11$77.12M1.48886,213 shs960,155 shsIZTCInvizyne Technologies$12.81-2.6%$12.59$8.50▼$23.00$80.09MN/A37,647 shs166 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group0.00%+1.35%+4.09%+0.73%+926.12%GALTGalectin Therapeutics0.00%+3.79%+3.79%-18.45%-49.82%IMUXImmunic0.00%+2.09%-19.16%-30.01%-36.12%IZTCInvizyne Technologies-2.59%-4.66%-11.96%-16.55%+1,280,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFNCHFinch Therapeutics Group0.3389 of 5 stars0.03.00.00.00.01.70.6GALTGalectin Therapeutics1.1487 of 5 stars3.00.00.00.02.61.70.0IMUXImmunic3.0379 of 5 stars3.63.00.00.02.72.50.6IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFNCHFinch Therapeutics Group 0.00N/AN/AN/AGALTGalectin Therapeutics 2.00Hold$11.00702.92% UpsideIMUXImmunic 3.25Buy$11.601,341.17% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FNCH, IMUX, GALT, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $10.005/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/15/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/10/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/2/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/1/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFNCHFinch Therapeutics Group$110K200.75N/AN/A$14.25 per share0.96GALTGalectin TherapeuticsN/AN/AN/AN/A($1.01) per shareN/AIMUXImmunicN/AN/AN/AN/A$0.64 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AGALTGalectin Therapeutics-$41.07M-$0.72N/AN/AN/AN/AN/A-163.15%8/11/2025 (Estimated)IMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%8/6/2025 (Estimated)IZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest FNCH, IMUX, GALT, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFNCHFinch Therapeutics GroupN/A3.873.87GALTGalectin TherapeuticsN/A1.131.13IMUXImmunicN/A2.712.71IZTCInvizyne TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFNCHFinch Therapeutics Group21.77%GALTGalectin Therapeutics11.68%IMUXImmunic51.82%IZTCInvizyne TechnologiesN/AInsider OwnershipCompanyInsider OwnershipFNCHFinch Therapeutics Group44.90%GALTGalectin Therapeutics50.10%IMUXImmunic4.60%IZTCInvizyne TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataGALTGalectin Therapeutics963.29 million31.32 millionOptionableIMUXImmunic7095.82 million87.38 millionOptionableIZTCInvizyne Technologies296.25 millionN/AN/AFNCH, IMUX, GALT, and IZTC HeadlinesRecent News About These CompaniesHead to Head Survey: Invivyd (NASDAQ:IVVD) and Invizyne Technologies (NASDAQ:IZTC)June 11, 2025 | americanbankingnews.comCitadel Advisors LLC Invests $456,000 in Invizyne Technologies Inc. (NASDAQ:IZTC)June 3, 2025 | marketbeat.comInstitutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)February 13, 2025 | uk.finance.yahoo.comWhat’s in a Name: Out with Invizyne, In with eXoZymesFebruary 12, 2025 | genengnews.comInvizyne Technologies rebrands as eXoZymes with new ticker EXOZFebruary 11, 2025 | msn.comInvizyne announces corporate name change to eXoZymesFebruary 11, 2025 | markets.businessinsider.comWhy Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%February 5, 2025 | aaii.comWhy Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%January 30, 2025 | aaii.comInvizyne technologies CEO Michael Heltzen buys $20,345 in stockJanuary 21, 2025 | msn.comInvizyne Technologies Inc trading resumesJanuary 1, 2025 | markets.businessinsider.comInvizyne Technologies Inc trading halted, volatility trading pauseJanuary 1, 2025 | markets.businessinsider.comMichael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) StockNovember 20, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFNCH, IMUX, GALT, and IZTC Company DescriptionsFinch Therapeutics Group NASDAQ:FNCH$13.75 +0.87 (+6.75%) As of 06/13/2025 03:35 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Galectin Therapeutics NASDAQ:GALT$1.37 +0.03 (+2.24%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.44 +0.07 (+5.40%) As of 06/13/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Immunic NASDAQ:IMUX$0.80 -0.04 (-4.62%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.81 +0.01 (+0.88%) As of 06/13/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Invizyne Technologies NASDAQ:IZTC$12.81 -0.34 (-2.59%) As of 06/13/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
